KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Teladoc Health (TDOC) Research & Development (2016 - 2025)

Teladoc Health's Research & Development history spans 12 years, with the latest figure at $71.6 million for Q4 2025.

  • For Q4 2025, Research & Development fell 6.7% year-over-year to $71.6 million; the TTM value through Dec 2025 reached $277.9 million, down 9.55%, while the annual FY2025 figure was $277.9 million, 9.55% down from the prior year.
  • Research & Development for Q4 2025 was $71.6 million at Teladoc Health, up from $67.6 million in the prior quarter.
  • Across five years, Research & Development topped out at $89.9 million in Q4 2023 and bottomed at $67.6 million in Q3 2025.
  • The 5-year median for Research & Development is $79.5 million (2021), against an average of $79.0 million.
  • The largest YoY upside for Research & Development was 305.09% in 2021 against a maximum downside of 21.39% in 2021.
  • A 5-year view of Research & Development shows it stood at $72.9 million in 2021, then grew by 13.81% to $82.9 million in 2022, then increased by 8.45% to $89.9 million in 2023, then fell by 14.66% to $76.8 million in 2024, then decreased by 6.7% to $71.6 million in 2025.
  • Per Business Quant, the three most recent readings for TDOC's Research & Development are $71.6 million (Q4 2025), $67.6 million (Q3 2025), and $68.8 million (Q2 2025).